^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Magicell-NK
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Medigen Biotech
Drug class:
NK cell stimulant
Related drugs:
10d
Phase I/II Study: Allogeneic NK-cell Therapy with Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients (clinicaltrials.gov)
P1/2, N=42, Recruiting, Medigen Biotechnology Corporation
New P1/2 trial • Surgery • Post-surgery
|
oxaliplatin • Magicell-NK
23d
A Phase I, Autologous ex Vivo Expanded and Activated NK Cell, Magicell-NK, Infusion for Colon Cancer Post Resection Study (clinicaltrials.gov)
P1, N=18, Recruiting, Medigen Biotechnology Corporation | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2026
Trial completion date • Trial primary completion date
|
Magicell-NK
over1year
Development of allogenic nonviral RNA-based CAR-NK therapy targeting CDH17 in relapsed/refractory gastrointestinal cancer. (ASCO 2023)
Ex vivo expanded human peripheral blood NK (Magicell-NK, Medigen, Taiwan) cells were used in this study. Our findings suggest that a non-viral based CDH17 CAR-NK cell therapy could be a potential allogeneic, off-the-shelf CAR-NK therapy candidate in GI cancer and support the rationale of further investigating it in vivo and clinical trials.
IO biomarker
|
TNFA (Tumor Necrosis Factor-Alpha) • LAMP1 (Lysosomal Associated Membrane Protein 1) • CDH17 (Cadherin 17)
|
CDH17 CAR-NK cell therapy • CHM 2301 • Magicell-NK
over2years
A Phase I, Autologous ex Vivo Expanded and Activated NK Cell, Magicell-NK, Infusion for Colon Cancer Post Resection Study (clinicaltrials.gov)
P1, N=18, Recruiting, Medigen Biotechnology Corporation
New P1 trial • Preclinical • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CA 19-9 (Cancer antigen 19-9)
|
Magicell-NK
Share via
